- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
5 Biggest Biotechnology ETFs in 2024
For investors looking for less volatility compared to stocks, here’s an overview of the five largest biotechnology ETFs for consideration.
Investing in the biotech industry can be a long road to gains given the sector’s volatility.
Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.
An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.
1. SPDR S&P Biotech ETF (ARCA:XBI)
Total assets: US$8.153 billion
Established on February 6, 2006, the SPDR S&P Biotech ETF is a largely balanced fund in terms of weight that focuses mostly on biotech companies with some pharmaceutical companies. As noted by ETF.com, it focuses on small- and micro-cap companies, which makes the weight of each holding smaller than the holdings of other ETFs in this sector.
The SPDR S&P Biotech ETF has 122 companies in its portfolio, with the top three being: Viking Therapeutics (NASDAQ:VKTX) which has a 4.5 percent weighting; Iovance Biotherapeutics (NASDAQ:IOVA) weighted at 2.5 percent; and Cytokinetics (NASDAQ:CYTK) with a 2.22 percent weight.
2. iShares NASDAQ Biotechnology ETF (NASDAQ:IBB)
Total assets: US$7.78 billion
The iShares NASDAQ Biotechnology ETF was launched on February 5, 2001, and tracks 220 holdings. This iShares ETF is a diversified fund in that it provides exposure to biotechnology, pharmaceutical and life science tools and services. Its overarching investment goal is to track NASDAQ-listed companies focused on these areas.
Its top three holdings are: Vertex Pharmaceuticals (NASDAQ:VRTX), weighted at 8.82 percent; Regeneron Pharmaceuticals (NASDAQ:REGN) with a 8.72 percent weight; and Amgen (NASDAQ:AMGN) at a weight of 7.55 percent.
3. ARK Genomic Revolution Multi-Sector ETF (ARCA:ARKG)
Total assets: US$1.915 billion
The ARK Genomic Revolution Multi-Sector ETF came into existence on October 31, 2014, and tracks 43 holdings. This ETF follows companies that develop products such as CRISPR technology, bioinformatics, molecular diagnostics and stem cells.
This top biotechnology ETF's three most significant company holdings are: CRISPR Therapeutics (NASDAQ:CRSP), weighted at 8.21 percent; Recursion Pharmaceuticals (NASDAQ:RXRX) at a weight of 6.45 percent; and Twist Bioscience (NASDAQ:TWST) at 5.97 percent.
4. Direxion Daily S&P Biotech Bull 3x Shares ETF (ARCA:LABU)
Total assets: US$1.36 billion
Founded on May 28, 2015, the Direxion Daily S&P Biotech Bull 3x Shares ETF does not mirror an index. Instead, its goal is to obtain daily investment results of at least 300 percent of the S&P Biotechnology Select Industry Index.
Like some of the other ETFs on this list, companies in the Direxion Daily S&P Biotech Bull 3x Shares ETF have an equally weighted average. Its top holdings include: Viking Therapeutics (NASDAQ:VKTX), which has a 3.13 percent weight; Iovance Biotherapeutics with a weight of 1.95 percent; and Cytokinetics at a weight of 1.87 percent.
5. First Trust NYSE Arca Biotechnology Index (ARCA:FBT)
Total assets: US$1.189 billion
The First Trust NYSE Arca Biotechnology ETF entered the market on June 23, 2006, and aims to track the NYSE Arca Biotechnology Index as closely as it can. Companies in this fund are generally involved in areas such as recombinant DNA technology, molecular biology, genetic engineering and genomics.
The fund has only 31 holdings; this means they are largely equally weighted. The top three holdings of the fund are the following large-cap companies: Natera (NASDAQ:NTRA) at a 4.78 percent weighting; Bruker Corporation (NASDAQ:BRKR) representing a 4.09 percent weight, and Halozyme Therapeutics (NASDAQ:HALO), coming in at a 3.89 percent weight.
This is an updated version of an article first published by the Investing News Network in 2016.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
- Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2023 ›
- Top 3 Canadian Biotech Stocks ›
- How to Invest in Biotechnology ›
- 5 US Longevity Stocks to Watch ›
- Biotech Market Forecast: Top Trends That Will Affect Biotech in 2024 ›
- 5 Small Biotech ETFs | INN ›
Melissa Pistilli has been reporting on the markets and educating investors since 2006. She has covered a wide variety of industries in the investment space including mining, cannabis, tech and pharmaceuticals. She helps to educate investors about opportunities in a variety of growth markets. Melissa holds a bachelor's degree in English education as well as a master's degree in the teaching of writing, both from Humboldt State University, California.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Melissa Pistilli has been reporting on the markets and educating investors since 2006. She has covered a wide variety of industries in the investment space including mining, cannabis, tech and pharmaceuticals. She helps to educate investors about opportunities in a variety of growth markets. Melissa holds a bachelor's degree in English education as well as a master's degree in the teaching of writing, both from Humboldt State University, California.
Learn about our editorial policies.